Comparison of the effect of Melatonin and Clonazepam on the REM sleep behavior disorder of patients with Parkinson's disease

Comparison of the effect of Melatonin and Clonazepam on the REM sleep behavior disorder of patients with Parkinson's disease, a double blind randomized trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170821035819N3

Enrollment

Registered

2020-02-16

Start date

2019-06-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

REM sleep behavior disorder of patients with Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Patients with Parkinson's disease who have sleep disorder, Take 3 mg Melatonin, once a night before bedtime, for one month (This drug is manufactured by Tehran Chem

Eligibility

Sex/Gender

All

Age

No minimum to 65 Years

Inclusion criteria

Inclusion criteria: Patients with Parkinson's who have REM sleep disorder based on history and questionnaire

Exclusion criteria

Exclusion criteria: Dementia A history of drug sensitivity

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: First time and After 1 month. Method of measurement: Pittsburgh sleep quality questionnaire.;Daytime sleepiness. Timepoint: First time and After 1 month. Method of measurement: Epworth sleepiness score questionnaire.;REM Sleep Disorder. Timepoint: First time and After 1 month. Method of measurement: REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVajiheh Aghamollaii

Tehran University of Medical Sciences

vajiheh102@gmail.com+98 21 5541 9151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026